"Designing Growth Strategies is in our DNA"
Region : | Published Date: Upcoming | Report ID: FBI100982| Status : Pipeline
A brain hemorrhage refers to a medical condition where there is bleeding in the brain and is also alternatively referred to as intracranial hemorrhage or a brain bleed. A brain hemorrhage is a type of stroke, where an artery in the brain bursts and results in localized bleeding in the surrounding tissues. A brain hemorrhage is a life-threatening condition and it is critical to receive adequate medical attention immediately. Brain hemorrhages are common and account for 13% of all the strokes occurring.
Some of the factors contributing to the occurrence of brain hemorrhages include head injuries or trauma, brain aneurysm, brain tumor, high blood pressure, bleeding disorders or blood vessel abnormalities. Some of the symptoms of brain hemorrhage include severe and sudden headache, problems with vision, loss of balance and coordination, seizures, slurred speech and confusion or difficulties in understanding. Some of the diagnosis options for brain hemorrhages include CT scans, MRI, X-rays of the brain and lumbar puncture (spinal tap).
Pharmaceutical companies and various research institutes have been focusing on studying and developing new treatment options for brain hemorrhage. For instance; PG2, which is being studied by PhytoHealth Corporation, is currently in early phase-1 clinical trials for the pilot clinical study on hemorrhagic stroke.
To get details on market share, speak to our analyst
At present more than 60% of the pipeline candidates for Brain Hemorrhage are in the phase-1 and phase-2 stage. Majority of the studies are sponsored by industry and government institutions.
The report on ‘Brain Hemorrhage – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Brain Hemorrhage. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Brain Hemorrhage.
The report on ‘Brain Hemorrhage – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.